SITAgliptin for Depressive Symptoms in Type 2 Diabetes: A Feasibility Randomized Controlled Trial

Conclusions Repositioning of oral hypoglycemic therapy for depressive symptoms in T2D is feasible. However, in this unpowered feasibility study, we did not detect evidence of superiority of sitagliptin over placebo. The results are cautioned by the small sample size and limited treatment duration. Trial Registration: EudraCT: 2015–004527-32.
Source: Psychosomatic Medicine - Category: Psychiatry & Psychology Tags: ORIGINAL ARTICLES Source Type: research